MetPath Review Center

Enriching the minds of laboratory scientists worldwide

MetPath has achieved 100% PASSING rate in ASCP/AMT/HA-AD/AIMS exams, worldwide.

REVIEW SCHEDULES (September 2018 PHIL Board Exam)

1st batch: APR 2, 2018
2nd batch: MAY 2, 2018
3rd batch: JUN 4, 2018
4th batch: JUL 2, 2018 
5th batch: JUL 16, 2018
6th batch: AUG 6, 2018 
Each batch will take two (2) intensive review months.
Applicable for In-House and Online Review.

For ASCP/HAAD/AIMS, START your review ANYTIME once enrolled.

Welcome to MetPath!

MetPath is an exclusive center for medtech review
and assistance program since 1999 for any medical technology / laboratory science examinations, such
as local or state board exams, as well as, national or international exams, worldwide.

Our MLS/CLS review course consists of comprehensive and dynamic live interactive lectures and cover all areas
of laboratory practices (blood banking, chemistry, hematology, immunology, microbiology, urinalysis,
body fluids, and laboratory operations). 

This program is designed to give students an in depth perspective of medical laboratory science practices and provide them with the knowledge and confidence to successfully pass any MLS/CLS exams. 

We wish that you take time browsing our site and find it helpful to enhance your medical laboratory science profession.


MedTech Graduates are welcome to join us at

Davao is World's 87th Top City

DAVAO is the only Philippines city included in the Top 100, Davao City placed 87th in the list of fastest-growing cities and urban areas in the world. (published Nov. 2011)

          MetPath invites YOU to the Largest City in the World! 

MetPath is conveniently located in the heart of Davao, the Philippines' most safest and cleanest city. Davao is an ideal place to learn and refresh your mind amidst the urban traffic and polutions elsewhere. Not to mention, Davao is absolutely
typhoon-free where everyone enjoys good weather all year round. Most of all, the high quality of life does not come at a high cost in
Davao City.  

 Visit our PHOTO GALLERY to take a sneak view of DAVAO. 

MetPath News and Updates!


MetPath limited offer . Get as much as 10% OFF the regular review fee yet enjoy the same benefits such as; 

FREE MetPath Review Notes

FREE Intensive Final Coaching

GET 50% off your review fee for international MLS/MT exams.

Promo applies to any group of 12 or more students who graduated from the same school and batch. For details and reservations, CONTACT US.




Monday - Thursday
7:00PM-10:00PM (PHIL Time)

This is to better accomodate our fellow reviewees who are working during daytime and other parts of the world.


*Applies only to Online Review Program for ASCP/AMT/HA-AD/CSMLS/AIMS/QCHP. 






Shulamitte Faith Faburada, MLS(ASCP)
Janine Anne Juyo, MLS(ASCP)
Margarette Denila, MLS(ASCP)
Reymond Lim, MLS(ASCP)
Johanna Maree Crave, MLS(ASCP)
Eanne Jairah Reyes, MLS(ASCP)
Stella Ramirez, MLS(ASCP)
Lee Marco Mutia, MLS(ASCP)
Mary Clare Cesar, MLS(ASCP)
Mariam Louise Nisal, MLS(ASCP)

Main Center

104 Jaltan Bldg.
CM Recto cor Bonifacio Street,
Davao City 8000, PHL         

DTI Cert. No. 00147471

Share MetPath to a friend

Recent Diagnostic Posts

Safety Tests Of Ebola Vaccines To Start This Fall.


The AP (Perrone, Neergaard) reports that safety trials are to begin for two experimental Ebola vaccines. Safety tests “typically are performed on a few dozen to 100 people.” The first, “developed by researchers at the National Institutes of Health” and GlaxoSmithKline should be tested in the next few months and is “based on a chimpanzee adenovirus.” Dr. Anthony Fauci has explained that it is “purely preventive, more aimed at giving it to the health care workers who put themselves at considerable danger.” The second, developed by researchers at the Canadian national laboratory and NewLink Genetics of Ames, Iowa, is expected to be tested “in up to 100 health volunteers with the FDA” though the timetable has not been set. The NIH is also supporting development of “at least two other candidate Ebola vaccines,” the first from Crucell, which “could begin human testing by late 2015,” and the second from Profectus Biosciences.